Object. Subarachnoid hemorrhage (SAH)-induced vasospasm is a significant underlying cause of aneurysm rupture-related morbidity and death. While long-term intravenous infusion of sodium nitrite (NaNO 2 ) can prevent cerebral vasospasm after SAH, it is not known if the intravenous administration of this compound can reverse established SAH-induced vasospasm. To determine if the intravenous infusion of NaNO 2 can reverse established vasospasm, the authors infused primates with the compound after SAH-induced vasospasm was established.
T
here are approximately 27,000 new cases of aneurysm-related SAH every year in the US (10 cases/100,000 persons). Between 30% and 60% of patients who survive the initial aneurysm rupture will go on to experience vasospasm of the cerebral vasculature between Days 3 and 12 post-SAH. 31 Despite optimized surgical and medical treatment, approximately 30% of these patients will suffer major neurological deficits 4, 13 related to vasospasm, with a mortality rate over 25% by 6 months after aneurysm rupture. 16 Because of the lack of effective treatment paradigms, we need new therapeutic options that target the underlying pathophysiology of SAH-related cerebral vasospasm after aneurysm rupture and reverse its effects.
Emerging evidence indicates that NO plays a critical role in cerebral vasospasm development. 19, 28 Specifically, the reduced availability of endo-and perivascular NO has been shown to directly contribute to vasospasm development after aneurysm rupture. 21 Nitric oxide replacement therapy using classic donors (sodium nitroprusside and nitroglycerin) in the experimental setting has been shown Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates to prevent vasospasm. However, the high rate of significant adverse effects (significant drop in blood pressure, drug tolerance, and rebound phenomenon) associated with these agents has prevented their effective clinical use, 27 leading to the investigation of new NO donors and treatment paradigms.
The clinical and pharmacological properties of NaNO 2 indicate that it may be an ideal NO donor for the treatment of a variety of conditions responsive to NO replacement. 2 Recently, the intravenous infusion of NaNO 2 has been used to effectively dilate peripheral vasculature in the presence of deoxygenated hemoglobin. 5 Further, recent data have shown that the infusion of NaNO 2 can be performed safely for prolonged periods without the side effects associated with other NO donors. 19, 20 While intravenous NaNO 2 can effectively prevent SAH-induced cerebral vasospasm in primates, 19 it is not known if it can reverse established SAH-associated vasospasm.
To determine if intravenous NaNO 2 can reverse established cerebral vasospasm, we investigated the intravenous infusion of NaNO 2 for the treatment of established SAH-associated cerebral vasospasm in primates.
Methods

Animal Population
Fourteen cynomolgus macaques (3-12 kg) were included in the study. All animal experiments were approved by the Animal Care and Use Committee of the National Institute of Neurological Disorders and Stroke at the NIH.
Anesthesia Protocol
General anesthesia was induced by the injection of ketamine (10 mg/kg) and xylazine (1 mg/kg) followed by tracheal intubation. Anesthesia was maintained by inhaled isoflurane (0.5%-1.0%).
18 Blood pressure, heart rate, rectal body temperature, and end-tidal CO 2 were continuously monitored during anesthesia and drug infusion. Sodium thiopental (25 mg/kg) and cefazolin (500 mg) were injected at the beginning of cranial surgery.
Arteriographic Studies
For digital subtraction arteriography the right femoral artery was exposed and a 3-Fr catheter including guidewire (F3 polyethylene, Cook Group Co.) was introduced into the right carotid artery under fluoroscopic guidance. One milliliter of contrast medium (Isovue-300, Bracco Diagnostics, Inc.) was injected, and arteriograms were acquired at a rate of 8 images per second. A ruler with a millimeter scale was placed at a standardized position by the head of each animal and was used for the calibration of every image. Three blinded examiners measured the area of the proximal 14 mm of the right MCA by using digital image analysis software (NIH Image J) 3 times, and the mean value was used for statistical analysis. The percent reduction in the ratio of the area measured on the serial arteriograms was compared with the ratio computed from the baseline arteriogram, defining the degree of vasospasm by the equation, diameter = area/length.
Subarachnoid Hemorrhage Clot Placement
The SAH model is described in detail elsewhere. 7, 19 Briefly, after creating a right frontotemporal craniectomy and opening the dura mater, the arachnoid of the sylvian fissure was dissected from the proximal 14 mm of the right MCA, distal internal carotid artery, and proximal anterior cerebral artery. Autologous blood was collected from the left femoral artery and allowed to clot for approximately 15 minutes. Five milliliters of clot was placed around the exposed arteries. After closing the dura and the wound, animals were returned to their cages for monitoring of clinical parameters including neurological deficits and postoperative course.
Sodium Nitrite
The NaNO 2 was obtained from the NIH Pharmacy (Clinical Center at the NIH), dissolved in 15 ml of phosphate-buffered saline, and filtered through a 0.2-mm filter. The treatment dose was derived from the maximum tolerated dose in a healthy human volunteer phase I safety and toxicity study. 20 
Experimental Design
Animals underwent arteriography 2 weeks before SAH to assess the baseline diameter of cerebral arteries and on post-SAH Day 7 to confirm the presence of cerebral vasospasm. Once cerebral vasospasm was confirmed, animals were randomly allocated to 2 groups (control and treatment), and the intravenous infusion of saline (control, 3.3 ml/hr) or NaNO 2 (treatment, 3.3 ml/hr [300 mg/kg/ hr]) was started immediately. The duration of the NaNO 2 infusion was either 3 hours (7 monkeys) or 8 hours (2 monkeys). Additional arteriograms were obtained immediately upon cessation of the infusion (14 animals) and at 2 (12 animals), 4 (1 animal), 6 (1 animal), and 8 hours (2 animals) after ceasing the infusion. Animals undergoing 8-hour NaNO 2 infusions had arteriograms at 3, 5, and 8 hours during the infusion.
Venous blood samples (1 ml) were collected at the time of craniectomy (14 animals); at the beginning of the infusion (14 animals); at 1.5 (14 animals) and 3 hours (14 animals) during the infusion; and at 2 (7 animals), 4 (2 animals), and 8 hours (2 animals) after ceasing the infusion. Both animals with prolonged infusions had additional blood collections at 5, 6.5, and 8 hours during the infusions. Cerebrospinal fluid samples were collected from the basal cisterns at the time of surgery and via suboccipital puncture after the final arteriogram.
Animals were euthanized with an intravenous overdose of pentobarbital (90 mg/kg) while under general anesthesia and after the completion of arteriography and blood and CSF collections.
Nitric Oxide Metabolome Measurements
Two hundred fifty microliters of NO 2 -stabilizing solution 15 was added to the blood samples immediately after collection to stabilize the NO metabolome. Levels of NO 2 , NO 3 , and SNOs in whole blood and CSF were measured using a chemiluminescence technique (model 280i NO analyzer, Sievers Instruments), as described by MacAr-thur et al. 15 Whole blood samples were treated with a 1:1 volume of ice-cold methanol and then were processed in a centrifuge at 4°C and 17,900 G for 5 minutes. Both the NO 2 and SNO concentrations were measured in acidic triiodide (I 3 -) reagent. Forty microliters of supernatant was injected into the purge vessel for NO 2 measurement. To identify NO 2 versus SNO, samples were incubated with and without acidified sulfanilamide, and 200 ml was injected into the I 3 -reductant. The NO 3 was measured by reduction in 10 ml of vanadium (III) at 90°C. Cerebrospinal fluid supernatant was thawed and then processed in a centrifuge at 4°C and 17,900 G for 5 minutes, and pure supernatant was analyzed for NO 2 , NO 3 , and SNOs.
Statistical Analysis
All data were recorded in Excel (Microsoft Corp.), and statistical tests were computed using JMP software (SAS, Inc.). The degree of vasospasm, concentration levels of the NO metabolomes, and physiological parameters were assessed using 2-tailed t-tests and analysis of variance followed by 1-way ANOVA. Statistical significance was defined as p < 0.05. Values are expressed as the means ± SDs, unless indicated otherwise.
Results
Clinical Findings
Neurological deficits developed in none of the primates after subarachnoid MCA clot placement. Arteriography and intravenous infusion of saline (5 animals) or NaNO 2 (9 animals) were well tolerated in all of the animals. Blood pressure, heart rate, respiratory rate, body temperature, and end-tidal CO 2 remained unaffected in the saline and NaNO 2 groups over the 3- (Fig. 1 ) and 8-hour infusions.
Angiographic Findings
Moderate-to-severe vasospasm of the right MCA was confirmed in all 14 primates on Day 7 post-SAH (mean reduction in artery diameter, 42.17% ± 11.9%; p < 0.005; Fig. 2 upper) without significant difference between control (36.2% ± 8.8%) and treatment groups (45.5% ± 12.5%; p > 0.05). After 3 hours of NaNO 2 infusion, the degree of vasospasm in the right MCA was significantly reduced to 26.9% ± 7.6% (mean increase in vessel diameter, 18.6% ± 11.5%; p < 0.005), while it remained unchanged after saline infusion (37.1% ± 10.5%, 5 animals; p > 0.05). Two hours after cessation of the NaNO 2 infusion, the reduction in vasospasm persisted (mean increase in vessel diameter, 17.8% ± 10.9%; p < 0.05; Fig. 3 ). The NaNO 2 -induced vasodilation lasted 4 hours after cessation of the infusion (1 animal; Fig. 2 upper), but at 6 and 8 hours the vessels respasmed (mean reduction in artery diameter, 38.4% ± 8.3%, 2 animals). Continuous NaNO 2 infusion over 8 hours maintained the significantly reduced degree of vasospasm (mean reduction in artery diameter, 32.3% ± 5.3% compared with 56.8% ± 23.1% after SAH; mean increase in artery diameter, 24.5% ± 17.8%; Fig. 2 lower) .
Metabolome Findings
Blood. Whole blood NO 2 , NO 3 , and SNO baseline levels on Day 7 after SAH did not differ between the control and treatment groups (p > 0.05). They remained unchanged during saline infusion (5 animals) and were significantly increased with NaNO 2 infusion. The NO 2 concentration increased 90 minutes after NaNO 2 infusion (p < 0.05) and peaked at 180 minutes at 3.7 ± 2.1 mmol/L (7 animals; p < 0.05). Two hours after ceasing the NaNO 2 infusion, the NO 2 levels returned to baseline (7 animals; Fig. 4A ) and remained unchanged at 4 and 8 hours (2 animals). The NO 3 levels increased after 90 minutes of infusion (p < 0.05) and peaked at 180 minutes at 18.2 ± 5.3 mmol/L (7 animals; p < 0.05). The NO 3 levels then remained elevated 2 hours after ceasing the infusion (p < 0.002) and returned to baseline (7.1 ± 1.3 mmol/L) at 4 and 8 hours (2 animals; Fig. 4B ). The SNO concentrations increased after 90 minutes of infusion (p < 0.05) and reached a peak (7 animals; 33.4 ± 11.4 nmol/L) after 180 minutes. Within 2 hours after ceasing the infusion, SNO levels returned to baseline (7 animals) and remained unchanged after 4 and 8 hours (2 animals; Fig. 4C ). During the 8-hour NaNO 2 infusions, the concentration of all 3 metabolites remained elevated.
Cerebrospinal Fluid. Control and treatment groups showed no significant difference in CSF concentrations of NO 2 , NO 3 , and SNO at baseline (p > 0.05). On SAH Day 7, the NO 2 levels were significantly decreased (p < 0.05), and the NO 3 and SNO levels remained unchanged in the control group as compared with pre-SAH levels. The NO 2 levels in the 3-hour NaNO 2 infusion group with short observation periods increased significantly compared with the control group (from 1.7 ± 0.4 to 4.9 ± 2.1 μmol/L; p < 0.005; Fig. 5A ), but the NO 3 levels in the same group were not significantly changed compared with controls. The NO 3 levels in CSF were significantly decreased in the treatment group (from 23.8 ± 6.2 to 7.5 ± 4.4 μmol/L; p < 0.05; Fig. 5B ). The differences between SNO levels before and after treatment were not significant in either group (p > 0.05; Fig. 5C ). All 3 metabolites increased in the CSF of the 2 primates that underwent prolonged 8-hour NaNO 2 infusions compared with the CSF concentrations at the time of SAH.
Discussion
Methods for Reversing Vasospasm
Currently available methods for reversing cerebral vasospasm after SAH include balloon angioplasty and/ or the direct intraarterial administration of papaverine/ nicardipine to the affected arteries, in addition to hemodynamic therapy. 8 While these methods have been shown to reverse established cerebral vasospasm, the effects are often transient and/or ineffective. 22, 23 Balloon angioplasty has size limitations with regard to dilating smaller distal arteries, while arteries may be impossible to access due to the angioarchitecture in the distal and posterior circulation. Further, intraarterial papaverine infusion for established vasospasm does not improve outcome due to its transient effects. 23, 29 Moreover, complications, including thromboembolism, vessel rupture, reperfusion hemorrhage, arterial dissection, and bleeding from untreated Middle cerebral artery diameter on Day 7 post-SAH was not significantly different between the control and treatment groups. Saline did not affect the degree of vasospasm, whereas NaNO 2 infusion increased the diameter of the spastic vessel by 18.6%. Follow-up arteriograms after infusion cessation revealed that the therapeutic effect persisted for 4 hours. Vessel spasm returned after 6 (1 animal) and 8 hours (2 animals). Lower: Graph depicting arteriographic results of 2 animals with prolonged 8-hour NaNO 2 infusions. The average degree of vasospasm was higher in these animals than in the 3-hour infusion group. At 8 hours, the MCA was still dilated in comparison with the baseline diameter after SAH (mean increase in artery diameter, 24.5% ± 17.8%). n = number of animals; ns = not significant.
aneurysms, have been associated with angioplasty (5%) and intraarterial papaverine infusion (9.9%). 10, 32 Additionally, papaverine infusions can result in an uncontrolled increase in intracranial pressure related to nonselective intracranial vasodilation and increased capacitance of the venous bed. 3 
Clinical Implications of NaNO 2 Infusion
Long-lasting intravenous infusion of NaNO 2 prevents vasospasm in a primate model. 19 However, the prevention of vasospasm is of value only if patients are admitted before its onset and if NaNO 2 infusion is initiated at that time. As current methods for reversing vasospasm carry high risks and reduced effectiveness and can require significant logistical efforts, effective, safe, and simplified treatment options are needed. In this study, we have shown that the intravenous infusion of NaNO 2 at a dose of 300 mg/kg/hr (adapted from the maximum tolerated dose in a healthy human volunteer study) 20 is safe and reverses SAH-induced cerebral vasospasm in primates. The intravenous route of NaNO 2 administration simplifies treatment delivery compared with the available intraarterial endovascular treatment options.
The nearly 20% dilation of the SAH-induced spastic arteries during NaNO 2 infusion results in hemodynamic changes that may improve cerebral perfusion. It has been shown that vessel diameter has a strong correlation with cerebral blood flow. 1, 9 Using the Hagen-Poiseuille equation as an approximate estimation for flow, in which flow increases to the fourth power of the vessel diameter, a 70% increase in blood flow could result from the increase in arterial diameter (18.6%) seen in these primates. Nevertheless, cerebral blood flow is dependent on various factors that can be broadly divided into those affecting cerebral perfusion pressure and those affecting the radius of cerebral blood vessels. To further define cerebral blood flow, cerebral blood volume, and intracranial pressure changes related to NaNO 2 , monitoring of these measures could be considered in future studies.
Prolonged observation in this study indicated that the therapeutic effect lasts for the duration of the infusion and approximately 4 hours after cessation of the infusion. Continuous infusion over 8 hours in 2 animals indicated that the therapeutic effect of NaNO 2 can be sustained if the infusion is not discontinued. Because it is safe and feasible to infuse NaNO 2 for prolonged periods of time (days), 20 continuous NaNO 2 infusion during spasms is possible and could provide continued therapeutic effect.
All animals tolerated the intravenous infusion of NaNO 2 well. We did not observe any relevant changes in heart rate, blood pressure, or respiratory rate in the primates under general anesthesia during the intravenous infusions of saline or NaNO 2 . Previous studies in nonhuman primates 19 and healthy human volunteers 20 using the same dose infused in this study, but over a much longer period, did not result in clinically relevant methemoglobinemia, another potential adverse effect of systemic NaNO 2 . These findings indicate that intravenous NaNO 2 can be infused safely at clinically relevant doses.
Mechanism of NaNO 2 Effect
Deprivation of NO in the vicinity of brain vasculature has been established as a cause of cerebral vasospasm after SAH. 12, 21 The underlying mechanism includes endothelial NO synthase dysfunction, 11, 30 reduction of neuronal NO synthase, and scavenging of NO by hemoglobin. 17, 21 Sodium nitroprusside and nitroglycerin are NO donors that have been studied clinically and have shown limited success. 24, 25 Major drawbacks with both agents were also nonselective vasodilation, short-lasting effects with rebound phenomenon, drug tolerance, and side effects including systemic hypotension, nausea, vomiting, and increased intracranial pressure. The chemical properties and adverse effects of both drugs have excluded them from routine clinical application and have led to discoveries of new classes of NO donors like NONOates (chemical compounds that spontaneously release NO when exposed to normal pH fluid) and NaNO 2 .
14 Recently, the prolonged intravenous infusion of NaNO 2 has been shown to be a potent peripheral vasodilator via the release of NO in the presence of deoxygenated hemoglobin. 5 Pharmacodynamic changes in NaNO 2 in the circulation can be measured by changes of the metabolome. The metabolome represents the complement of all the small-molecular-weight metabolites inside a sample of interest. The metabolome analyzed in the current study describes the dynamic changes in metabolites over short time lapses (seconds) during pharmacodynamic conversion of NaNO 2 to NO. Specifically, increased whole blood NO 2 concentration during infusion confirms the bioavailability of intravenous NaNO 2 . To determine if NO was released from NaNO 2 , we measured NO 3 and SNO concentrations in whole blood. Nitric oxide reacts with both oxyhemoglobin and deoxyhemoglobin, forming NO 3 in a nearly diffusion-limited reaction. Nitric oxide also reacts with intravascular circulating thiols forming SNO. Consistent with the reduction of NO 2 to NO, both NO 3 and SNO levels in whole blood were increased during infusion. 2, 6 Further, as verified in the CSF of these animals as well as in other studies, decreased NO 2 CSF levels after SAH reveal the important role that NO replacement therapy plays in treating vasospasm after SAH. 12, 19, 26 The sig- nificant increase in CSF NO 2 concentration in the treatment group also confirms that intravenously delivered NaNO 2 penetrates into the CSF and that the NO 2 deficit after SAH can be reversed by NaNO 2 administration.
Sodium nitrite has a unique, selective, and local mechanism of NO release as compared with traditional NO donors because NO is released from NaNO 2 under acidic and hypoxic conditions in the presence of deoxyhemoglobin, acting in a local fashion as an on-demand NO 2 reductase. 2 The conversion of NO 2 to NO and SNO is mediated by the reaction with deoxyhemoglobin. This reaction provides a means for hypoxia-regulated production of NO by erythrocytes, tissue heme proteins, and endothelium. 2 These conditions are present locally in the spastic vessels after SAH. Sodium nitrite infusions in healthy humans did not produce any clinical signs of increased intracranial pressure, such as headache or nausea, consistent with the lack of dilation in normal cerebral vasculature. 20 However, whether NaNO 2 is acting selectively on spastic intracranial vessels must be further confirmed in patients with SAH in future studies.
Potential Study Limitations
While the current study data provide direct insight into the potential therapeutic effects of NaNO 2 , there are potential limitations of this animal model of SAH. Animal models do not reflect the entire clinical condition of patients with aneurysmal SAH. Cardiac dysfunction, hydrocephalus, and increased intracranial pressure, which can occur in patients with SAH, are not reflected in this model. Further, combinations of other pharmaceutical agents in patients with SAH, such as calcium channel blockers, could affect NaNO 2 pharmacodynamics and may require further investigation.
Conclusions
Intravenous infusion of NaNO 2 is safe and effective for reversing established cerebral vasospasm after SAH in a primate model. These findings indicate that this treatment strategy may be useful in reversing cerebral vasospasm after aneurysmal SAH. 
